Apotex gets FDA warning regarding contamination at Toronto plant

04/15/2010 | New York Times (tiered subscription model), The

The FDA sent a warning letter to generic-drug firm Apotex for failing to inform the agency about contamination involving an antihistamine and a diabetes drug produced at its plant in Toronto. The letter is the second time in less than a year that the FDA warned Apotex regarding manufacturing violations. The company did not respond to a newspaper's requests for comment.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI